Company / R&D per Share
Organon & Co. R&D per Share History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.42
FY2025
5-year range
$0.87 / $2.08
FY2021-FY2025
Trend
-22.6%
vs FY2024
Sector context
#128 of 208
Health Care
What the data says
At $1.42, Organon & Co.'s r&d per share ranks #128 of 208 in the Health Care sector. Declined from $2.08 to $1.42 over the past 2 years.
Based on SEC 10-K filings.
1.42 in FY2025 with a 5-year CAGR of +11.4%.
Declined from $2.08 to $1.42 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -8.6%
- 5-Year CAGR
- +11.4%
- 10-Year CAGR
- -
Sector benchmark
#128 of 208 in Health CareTop 62% of 208This company $1.42 Sector average $12.19
▼
-88.4% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 22.6% year-over-year.
- Ranks #128 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 55.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.42 | -22.6% |
| FY2024 | $1.83 | -11.6% |
| FY2023 | $2.08 | +11.7% |
| FY2022 | $1.86 | +114.1% |
| FY2021 | $0.87 | +4.7% |
| FY2020 | $0.83 | -4.5% |
| FY2019 | $0.87 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026